Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 214,200 shares, an increase of 604.6% from the March 31st total of 30,400 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is presently 0.2 days.

Sonoma Pharmaceuticals Price Performance

SNOA remained flat at $0.16 during trading on Thursday. The company’s stock had a trading volume of 112,297 shares, compared to its average volume of 1,619,034. Sonoma Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $1.52. The company’s fifty day simple moving average is $0.15 and its two-hundred day simple moving average is $0.21. The company has a market cap of $2.50 million, a price-to-earnings ratio of -0.17 and a beta of 1.28.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Thursday, February 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.15. The business had revenue of $3.14 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 41.24% and a negative return on equity of 58.93%. On average, analysts forecast that Sonoma Pharmaceuticals will post -0.89 EPS for the current fiscal year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.